Damla Kelle, Kai R Speth, María Martínez-Negro, Volker Mailänder, Katharina Landfester, Banu Iyisan
{"title":"蛋白质电晕对聚乳酸(PLGA)纳米颗粒药物释放行为的影响","authors":"Damla Kelle, Kai R Speth, María Martínez-Negro, Volker Mailänder, Katharina Landfester, Banu Iyisan","doi":"10.1016/j.ejpb.2024.114611","DOIUrl":null,"url":null,"abstract":"<p><p>Poly(lactic-co-glycolide) (PLGA) nanoparticles are highly attractive for drug delivery due to their biocompatibility, biodegradability, and potential for controlled release and targeting. Despite these outstanding properties, challenges remain for clinical translation as nanomedicines. One significant factor to address is highlighting the protein corona structure and its effect on the drug release behavior. Protein corona forms upon contact with the bloodstream and influences the fate of the nanoparticles in the body. Here, we synthesize PLGA nanoparticles by miniemulsion/solvent evaporation technique, followed by the formation of protein corona on their surface using either human plasma or fetal bovine serum (FBS). Analysis by both sodium dodecyl sulfate-polyacrylamide gel electrophoresis (SDS-PAGE) and liquid chromatography-mass spectrometry (LC-MS) reveals that dysopsonin proteins, mainly albumin, dominate the protein corona structure, suggesting prolonged blood circulation for the PLGA nanoparticles. As an anticancer drug, doxorubicin is encapsulated into PLGA nanoparticles, and in vitro drug release is performed at pH 7.4. While there is a minimal change in cumulative drug release after protein corona formation, our comprehensive analysis through different kinetic models shows that the protein corona alters the drug release profile of PLGA nanoparticles to a modest extent.</p>","PeriodicalId":12024,"journal":{"name":"European Journal of Pharmaceutics and Biopharmaceutics","volume":" ","pages":"114611"},"PeriodicalIF":4.4000,"publicationDate":"2024-12-12","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":"{\"title\":\"Effect of protein corona on drug release behavior of PLGA nanoparticles.\",\"authors\":\"Damla Kelle, Kai R Speth, María Martínez-Negro, Volker Mailänder, Katharina Landfester, Banu Iyisan\",\"doi\":\"10.1016/j.ejpb.2024.114611\",\"DOIUrl\":null,\"url\":null,\"abstract\":\"<p><p>Poly(lactic-co-glycolide) (PLGA) nanoparticles are highly attractive for drug delivery due to their biocompatibility, biodegradability, and potential for controlled release and targeting. Despite these outstanding properties, challenges remain for clinical translation as nanomedicines. One significant factor to address is highlighting the protein corona structure and its effect on the drug release behavior. Protein corona forms upon contact with the bloodstream and influences the fate of the nanoparticles in the body. Here, we synthesize PLGA nanoparticles by miniemulsion/solvent evaporation technique, followed by the formation of protein corona on their surface using either human plasma or fetal bovine serum (FBS). Analysis by both sodium dodecyl sulfate-polyacrylamide gel electrophoresis (SDS-PAGE) and liquid chromatography-mass spectrometry (LC-MS) reveals that dysopsonin proteins, mainly albumin, dominate the protein corona structure, suggesting prolonged blood circulation for the PLGA nanoparticles. As an anticancer drug, doxorubicin is encapsulated into PLGA nanoparticles, and in vitro drug release is performed at pH 7.4. While there is a minimal change in cumulative drug release after protein corona formation, our comprehensive analysis through different kinetic models shows that the protein corona alters the drug release profile of PLGA nanoparticles to a modest extent.</p>\",\"PeriodicalId\":12024,\"journal\":{\"name\":\"European Journal of Pharmaceutics and Biopharmaceutics\",\"volume\":\" \",\"pages\":\"114611\"},\"PeriodicalIF\":4.4000,\"publicationDate\":\"2024-12-12\",\"publicationTypes\":\"Journal Article\",\"fieldsOfStudy\":null,\"isOpenAccess\":false,\"openAccessPdf\":\"\",\"citationCount\":\"0\",\"resultStr\":null,\"platform\":\"Semanticscholar\",\"paperid\":null,\"PeriodicalName\":\"European Journal of Pharmaceutics and Biopharmaceutics\",\"FirstCategoryId\":\"3\",\"ListUrlMain\":\"https://doi.org/10.1016/j.ejpb.2024.114611\",\"RegionNum\":2,\"RegionCategory\":\"医学\",\"ArticlePicture\":[],\"TitleCN\":null,\"AbstractTextCN\":null,\"PMCID\":null,\"EPubDate\":\"\",\"PubModel\":\"\",\"JCR\":\"Q1\",\"JCRName\":\"PHARMACOLOGY & PHARMACY\",\"Score\":null,\"Total\":0}","platform":"Semanticscholar","paperid":null,"PeriodicalName":"European Journal of Pharmaceutics and Biopharmaceutics","FirstCategoryId":"3","ListUrlMain":"https://doi.org/10.1016/j.ejpb.2024.114611","RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"Q1","JCRName":"PHARMACOLOGY & PHARMACY","Score":null,"Total":0}
Effect of protein corona on drug release behavior of PLGA nanoparticles.
Poly(lactic-co-glycolide) (PLGA) nanoparticles are highly attractive for drug delivery due to their biocompatibility, biodegradability, and potential for controlled release and targeting. Despite these outstanding properties, challenges remain for clinical translation as nanomedicines. One significant factor to address is highlighting the protein corona structure and its effect on the drug release behavior. Protein corona forms upon contact with the bloodstream and influences the fate of the nanoparticles in the body. Here, we synthesize PLGA nanoparticles by miniemulsion/solvent evaporation technique, followed by the formation of protein corona on their surface using either human plasma or fetal bovine serum (FBS). Analysis by both sodium dodecyl sulfate-polyacrylamide gel electrophoresis (SDS-PAGE) and liquid chromatography-mass spectrometry (LC-MS) reveals that dysopsonin proteins, mainly albumin, dominate the protein corona structure, suggesting prolonged blood circulation for the PLGA nanoparticles. As an anticancer drug, doxorubicin is encapsulated into PLGA nanoparticles, and in vitro drug release is performed at pH 7.4. While there is a minimal change in cumulative drug release after protein corona formation, our comprehensive analysis through different kinetic models shows that the protein corona alters the drug release profile of PLGA nanoparticles to a modest extent.
期刊介绍:
The European Journal of Pharmaceutics and Biopharmaceutics provides a medium for the publication of novel, innovative and hypothesis-driven research from the areas of Pharmaceutics and Biopharmaceutics.
Topics covered include for example:
Design and development of drug delivery systems for pharmaceuticals and biopharmaceuticals (small molecules, proteins, nucleic acids)
Aspects of manufacturing process design
Biomedical aspects of drug product design
Strategies and formulations for controlled drug transport across biological barriers
Physicochemical aspects of drug product development
Novel excipients for drug product design
Drug delivery and controlled release systems for systemic and local applications
Nanomaterials for therapeutic and diagnostic purposes
Advanced therapy medicinal products
Medical devices supporting a distinct pharmacological effect.